GlassScriptPhysician profile
Megan Joint
NPI 1538429055
$5,377.08
in general payments reported to CMS, 2019-2025
29 companies · $1,684 in 2025
The $1,684 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $495 · 2020: $21.45 · 2021: $424 · 2022: $968 · 2023: $1,244 · 2024: $540 · 2025: $1,684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,269 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,269.03 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $771.06 | 2019-2025 | Tremfya |
| Abbvie INC. | $769.86 | 2019-2025 | |
| Genzyme Corporation | $541.19 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $464.11 | 2022-2025 | Winlevi, Odomzo, Blu-U |
| Leo Pharma INC. | $333.38 | 2022-2025 | Adbry, Anzupgo, Spevigo |
| Journey Medical Corporation | $319.05 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $278.97 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $267.24 | 2021-2025 | Dupixent, Libtayo |
| Janssen Scientific Affairs, LLC | $260.31 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $191.43 | 2022-2025 | Sotyktu |
| Amgen INC. | $124.61 | 2023-2025 | Otezla, Otezla |
| Incyte Corporation | $124.33 | 2022-2025 | Opzelura |
| Lilly USA, LLC | $107.34 | 2022-2025 | Ebglyss |
| Almirall LLC | $106.03 | 2022-2024 | Klisyri, Seysara |
| Arcutis Biotherapeutics, INC. | $98.43 | 2023-2025 | Zoryve |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hill Dermaceuticals, INC. | $96.30 | 2023 | Tolak |
| Pfizer INC. | $83.79 | 2022-2023 | |
| Galderma Laboratories, L.P. | $70.02 | 2023 | Aklief, Twyneo, Oracea |
| Dermavant Sciences, INC. | $69.78 | 2023-2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.51 | 2025 | Spevigo |
| Organon LLC | $42.44 | 2025 | Vtama |
| Biofrontera INC. | $41.50 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Cipher Pharmaceuticals US LLC | $33.09 | 2025 | Natroba, Spinosad |
| Botanix Sb INC | $24.09 | 2025 | Sofdra |
| Medtronic, INC. | $22.16 | 2023 | Venaseal |
| Verrica Pharmaceuticals INC. | $18.35 | 2023 | Ycanth |
| Mayne Pharma Commercial LLC | $16.55 | 2023 | |
| Lnhc, INC | $16.52 | 2025 | Zelsuvmi |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $15.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Joint listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.